

Martin Bergstrand

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2535801/publications.pdf>

Version: 2024-02-01

22
papers

1,948
citations

687363

13
h-index

677142

22
g-index

22
all docs

22
docs citations

22
times ranked

2631
citing authors

#	ARTICLE	IF	CITATIONS
1	Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models. AAPS Journal, 2011, 13, 143-151.	4.4	1,057
2	PBPK models for the prediction of in vivo performance of oral dosage forms. European Journal of Pharmaceutical Sciences, 2014, 57, 300-321.	4.0	263
3	Handling Data Below the Limit of Quantification in Mixed Effect Models. AAPS Journal, 2009, 11, 371-380.	4.4	249
4	Population Pharmacokinetics of Busulfan in Children: Increased Evidence for Body Surface Area and Allometric Body Weight Dosing of Busulfan in Children. Clinical Cancer Research, 2011, 17, 6867-6877.	7.0	54
5	Population Pharmacokinetic and Pharmacodynamic Modeling of Amodiaquine and Desethylamodiaquine in Women with Plasmodium vivax Malaria during and after Pregnancy. Antimicrobial Agents and Chemotherapy, 2012, 56, 5764-5773.	3.2	44
6	Rapid Sample Size Calculations for a Defined Likelihood Ratio Test-Based Power in Mixed-Effects Models. AAPS Journal, 2012, 14, 176-186.	4.4	39
7	Population Pharmacokinetics of Tacrolimus in Pediatric Liver Transplantation: Early Posttransplantation Clearance. Therapeutic Drug Monitoring, 2011, 33, 663-672.	2.0	37
8	A mechanism-Based Approach for Absorption Modeling: The Gastro-Intestinal Transit Time (GIT) Model. AAPS Journal, 2012, 14, 155-163.	4.4	25
9	A strategy for residual error modeling incorporating scedasticity of variance and distribution shape. Journal of Pharmacokinetics and Pharmacodynamics, 2016, 43, 137-151.	1.8	22
10	A Semi-mechanistic Modeling Strategy to Link In Vitro and In Vivo Drug Release for Modified Release Formulations. Pharmaceutical Research, 2012, 29, 695-706.	3.5	18
11	Characterization of an in vivo concentration-effect relationship for piperazine in malaria chemoprevention. Science Translational Medicine, 2014, 6, 260ra147.	12.4	18
12	A Semi-mechanistic Modeling Strategy for Characterization of Regional Absorption Properties and Prospective Prediction of Plasma Concentrations Following Administration of New Modified Release Formulations. Pharmaceutical Research, 2012, 29, 574-584.	3.5	16
13	Prediction of Improved Antimalarial Chemoprevention with Weekly Dosing of Dihydroartemisinin-Piperazine. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	16
14	Population pharmacokinetic and pharmacodynamic properties of artesunate in patients with artemisinin sensitive and resistant infections in Southern Myanmar. Malaria Journal, 2018, 17, 126.	2.3	15
15	Meta-analysis of Magnetic Marker Monitoring Data to Characterize the Movement of Single Unit Dosage Forms Through the Gastrointestinal Tract Under Fed and Fasting Conditions. Pharmaceutical Research, 2016, 33, 751-762.	3.5	13
16	In Vitro and In Vivo Modeling of Hydroxypropyl Methylcellulose (HPMC) Matrix Tablet Erosion Under Fasting and Postprandial Status. Pharmaceutical Research, 2017, 34, 847-859.	3.5	12
17	Population Pharmacokinetic and Pharmacodynamic Modeling of Artemisinin Resistance in Southeast Asia. AAPS Journal, 2017, 19, 1842-1854.	4.4	12
18	Model-Based Prediction of Plasma Concentration and Enterohepatic Circulation of Total Bile Acids in Humans. CPT: Pharmacometrics and Systems Pharmacology, 2018, 7, 603-612.	2.5	12

#	ARTICLE	IF	CITATIONS
19	Pharmacokinetic modeling and simulation support for age- and weight-adjusted dosing of dabigatran etexilate in children with venous thromboembolism. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1259-1270.	3.8	12
20	Population pharmacokinetics of ticagrelor and AR-C124910XX in patients with prior myocardial infarction. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2017, 55, 416-424.	0.6	11
21	External Validation of the Bilirubin-Atazanavir Nomogram for Assessment of Atazanavir Plasma Exposure in HIV-1-Infected Patients. <i>AAPS Journal</i> , 2013, 15, 308-315.	4.4	2
22	Population Pharmacokinetics of Busulfan in Children-Response. <i>Clinical Cancer Research</i> , 2012, 18, 2717-2718.	7.0	1